SCHEMBL1745276

SCHEMBL1745276

O=C1NC(Cc2ccc(O)cc2)C(=O)S1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.45
GAA P10253 2/20 0.43
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRB3 P13945 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
KDM1A O60341 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
ITGB1 P05556 2/20 0.36
ITGA4 P13612 2/20 0.36
MAPT P10636 1/20 0.35
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
AKR1B1 P15121 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7632885 0.85 CXCR4 (0.38) CAPN1GAAADRB2ADRB1ADRA2A
SCHEMBL4940660 0.82 GAA (0.44) GAANR0B1
SCHEMBL5671980 0.82 ALDH1A1 (0.41) GAAMAPTTDP1
SCHEMBL8888904 0.81 ESR1 (0.38) CAPN1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL8887977 0.80 ESR1 (0.40) GAAADRA2AADRB3ADRA2BADRA2C
SCHEMBL3840339 0.79 GLA (0.47) HPGD
SCHEMBL8890490 0.79 ESR1 (0.42) GAAADRA2AADRB3ADRA2BADRA2C
SCHEMBL10516289 0.79 GAA (0.39) GAAADRB2ADRB1ADRA2AADRB3
SCHEMBL13399671 0.77 GAA (0.50) CAPN1GAAKDM1ADRD2DRD4
SCHEMBL13399253 0.77 GAA (0.50) CAPN1GAAKDM1ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104496935-A Synthetic method of insulin sensitizer intermediate SUZHOU JONATHAN NEW MATERIALS TECHNOLOGY CO LTD 2015-04-08 CN disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
CN-101463031-B Indazole and tetrahydrochysene indazole compounds, and preparation, pharmaceutical composition and use thereof INST MATERIA MEDICA CAMS 2014-02-12 CN disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
CN-101463031-A Indazole and tetrahydrochysene indazole compounds, and preparation, pharmaceutical composition and use thereof INST MATERIA MEDICA CAMS (CN) 2009-06-24 CN disclosed
JP-2009013091-A PRODUCTION METHOD OF PIOGLITAZONE HYDROCHLORIDE TOKUYAMA CORP 2009-01-22 JP disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed
WO-1992007838-A1 THIAZOLIDINE DIONE DERIVATIVES BEECHAM GROUP PLC (GB) 1992-05-14 WO disclosed
US-5063240-A Hypoglycemic, antilipemic BEECHAM GROUP P.L.C. (GB) 1991-11-05 US disclosed
EP-0208420-B1 THIAZOLIDINE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1991-09-18 EP disclosed
US-5002953-A Substituted Thiazolidinedione Derivatives BEECHAM GROUP P.L.C. (GB) 1991-03-26 US disclosed
EP-0397453-A1 Novel bis-2,4-dioxothiazolidines Beecham Group p.l.c. (GB) 1990-11-14 EP disclosed
EP-0177353-B1 THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1990-04-11 EP disclosed
US-4775687-A ANTIDIABETIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-10-04 US disclosed
US-4725610-A TREATMENT OF HYPERLIPEMIA AND DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-02-16 US disclosed
EP-0208420-A1 Thiazolidine derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1987-01-14 EP disclosed
EP-0177353-A2 Thiazolidinedione derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR CAPN1 3098/4885GAA 2417/4885ADRB2 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.